Physician profile
Michelle E Moore
NPI 1194795971
$5,378.15
in general payments reported to CMS, 2019-2025
18 companies · $1,024 in 2025
The $1,024 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $461 · 2020: $352 · 2021: $766 · 2022: $900 · 2023: $773 · 2024: $1,101 · 2025: $1,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,899.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,898.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,408.45 | 2022-2025 | Miebo, Infuse, Xiidra |
| Coopervision INC. | $688.50 | 2019-2025 | Myday Contact Lens, Misight Contact Lens, Clariti Contact Lens |
| Alcon Vision LLC | $678.55 | 2021-2025 | Total30, Precision7, Precision 1 |
| Sight Sciences, INC. | $537.84 | 2019-2025 | Tearcare System |
| Novartis Pharmaceuticals Corporation | $399.02 | 2020-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $387.68 | 2019-2021 | |
| Dompe US, INC. | $273.68 | 2020-2025 | Oxervate |
| Glaukos Corporation | $262.52 | 2022-2024 | Idose |
| Sun Pharmaceutical Industries INC. | $179.24 | 2020-2025 | Cequa |
| Abb Con-Cise Optical Group LLC | $151.47 | 2019-2025 | Contact Lens, Spectacle Lenses |
| Eyevance Pharmaceuticals LLC | $105.76 | 2021 | |
| Oyster Point Pharma, INC. | $86.72 | 2022-2023 | Tyrvaya |
| Johnson & Johnson Vision Care, INC. | $81.29 | 2019-2023 | Acuvue |
| Tarsus Pharmaceuticals, INC. | $49.31 | 2024 | Xdemvy |
| Allergan, INC. | $33.39 | 2021-2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $20.31 | 2019 | |
| Harrow Eye, LLC | $19.83 | 2024 | Vevye |
| Abbvie INC. | $14.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.